Question 1

How do I access the virtual meeting?

Accepted Answer

An email has been sent to all registered attendees with information on how to access the virtual meeting portal. 
 
If you've already registered and haven't received the email, please check your spam folder.
 
If you haven't registered yet, you will receive an email with the login details after you complete your registration.

Question 2

9.00-9.30 Networking - Virtual Coffee Meetup

Question 3

9.00-9.30 Networking - Virtual Coffee Meetup

Question 4

What time zone will the event be in?

Accepted Answer

All times listed in the event are Eastern Daylight Time (EDT). We have made considerations in scheduling our programming to serve the needs of our broad, globally-based audience as much as possible.
 
Please note that if you cannot join the live meeting the sessions will be available on demand for 60 days after the end of the symposium.

Question 5

9.30-9.45 Welcome & Opening Remarks

Accepted Answer

Mano Manoharan, PhD, IS3NA President
Alnylam Pharmaceuticals
Masad J. Damha, PhD, IS3NA Immediate Past President
McGill University

Question 6

9.30 - 10.50 Session V (part one)

Accepted Answer

Co-chairs: Steve Dowdy, PhD, and Laura Sepp-Lorenzino, PhD, Intellia Therapeutics

Development of Sugar-modified Oligonucleotides with Higher Enzymatic Stability Than PS Oligonucleotides
Satoshi Obika, PhD, Osaka University 
 
9.50-10.10
PNAs with Double Face: Bimodal PNAs as Templates for Supramolecular Assemblies of Nucleic Acids
Krishna N. Ganesh, FNA, FASc, FTWAS, Indian Institute of Science Education and Research 
 
10.10-10.30
Novel DNA-boron Cluster Conjugates with Two Faces
Barbara Nawrot, PhD, Polish Academy of Sciences
 
10.30-10.50
Improved Specificity of Conjugate siRNAs Through Chemical Modification
Mark K. Schlegel, PhD, Alnylam Pharmaceuticals

Question 7

Will presentations be available after the live broadcast?

Accepted Answer

Yes, presentations will be available for on-demand viewing for 60 days so that you can view them at your convenience. The content of the on-demand archive is dependent on allowance from speakers to rebroadcast their presentations as part of the on-demand archive. Attendees can expect a delay of up to 24 hours for on-demand recordings to be available.

Question 8

10.50-11.00 Break/Networking

Accepted Answer

Enter your answer here

Question 9

9.45 - 10.15 Keynote Presentation

Accepted Answer

Therapeutic Nucleosides and Evolution of Oligonucleotide Synthesis
Kelvin K. Ogilvie, PhD, Acadia University

Question 10

Will there be poster sessions?

Accepted Answer

While the virtual meeting will not have scheduled Poster Sessions, virtual posters will still be an integral part of the meeting and will be available for on demand viewing at your convenience.

Question 11

11.00-12.00 Session V (part two)

Accepted Answer

Co-chairs: Steve Dowdy, PhD, and Laura Sepp-Lorenzino, PhD, Intellia Therapeutics
 
11.00-11.20
New Backbone Chemistry Enhances the Drug-like Properties of Stereopure Oligonucleotides in Preclinical StudiesPachamuthu Kandasamy, PhD, Wave Life Sciences
 
11.20-11.40
In Vivo Therapeutic Genome Editing via Transient Expression of CRISPR/Cas9
Rubina Parmar, PhD, Intellia Therapeutics
 
11.40-12.00
Oligonucleotides Based Approaches for Treatment of Chronic Hepatitis B
Leonid Beigelman, PhD, Aligos Therapeutics

Question 12

10.15-11.15  Session I

Accepted Answer

Chair: Piet Herdewijn, PhD, KU Leuven
 
10.15-10.35
Design and Therapeutic Potential of Purinergic Receptor Ligands
Kenneth A. Jacobson, PhD, National Institute of Health
10.35-10.55
Discovery of Remdesivir and Beyond
Joy Feng, PhD, Gilead
10.55-11.15
Rapidly Advancing Transformational Therapeutic Solutions for Patients with Severe Viral Diseases
Jean-Pierre Sommadossi, PhD, Atea Pharmaceuticals

Question 13

11.15-11.30  Break / Networking

Question 14

What is the cost to attend?

Accepted Answer

Click here to view registration fees(https://www.is3na.org/2021-event-fees)

Question 15

12.00-12.30 Discussion

Accepted Answer

Co-chairs: Steve Dowdy, PhD, and Laura Sepp-Lorenzino, PhD, Intellia Therapeutics

Question 16

12.30-12.45 Break / Networking

Question 17

Do I have to be an IS3NA member to participate?

Accepted Answer

No. The Virtual Symposium is open to both members and nonmembers, but members will benefit by paying a lower registration rate. If you wish to become a member of IS3NA, you may complete your membership application simultaneously during your meeting registration.

Question 18

11.30-12.30 Session II

Accepted Answer

Chair: Victor E. Marquez, PhD, Chemical Biology Lab, NCI, NIH
 
11.30-11.50  
The Second Dimension of the Genetic Code
Thomas Carell, PhD, Ludwig-Maximilians-Universität München
11.50-12.10    
Synthesis of Novel 2’-disubstituted Ribonucleoside Analogs
Franck Amblard, PhD, Emory University 
12.10-12.30  
A de novo Nucleoside Synthesis: New Opportunities for Medicinal and Process Chemistry
Robert Britton, PhD, Simon Fraser University

Question 19

How do I access the abstract submission portal?

Accepted Answer

The submission portal is only available to registered meeting attendees. Once you register for the meeting, you will be emailed a confirmation with a link to the abstract submission portal. If you need assistance, email us at info@is3na.org.(mailto:info@is3na.org)

Question 20

12.45-13.55 Session VI

Accepted Answer

Co-chairs:  Yitzhak Tor, PhD, University of California, San Diego and Jean-Jacques Vasseur, PhD, Université de Montpellier

12.45-12.55
Lipid-oligonucleotide conjugates incorporating long-chain sulfonyl phosphoramidate groups: synthesis and biological properties
Alina Derzhalova, MSc., Novosibirsk State University
12.55-13.05
Regulation of circRNA expression in cell via RNA binding small molecule
Takeshi Yamada, PhD, Osaka University
13.05-13.15
5’-cap modified oligoribonucleotides with S-adenosyl-L-methionine analogs mimicking RNA 2’O-methylation transition state as original inhibitors against Dengue
Rostom Ahmed-Belkacem, PhD, Université de Montpellier
13.15-13.25
Simple chemical approaches to introduce 2,6-diaminopurine and 2-aminoadenine conjugates into oligonucleotides
Mimouna Madaoui, PhD, Alnylam Pharmaceuticals
13.25-13.35
Multi-functionalized gold nanoparticles for the delivery of gapmer oligonucleotides to target mutant p53 cancer cells
Eduardo García-Garrido, IMDEA Nanociencia
13.35-13.45
Promoter Recognition and Processive RNA Polymerization by a Clamping RNA Polymerase Ribozyme
Razvan Cojocaru, PhD, Simon Fraser University
13.45-13.55
Click and cut: Enzymatic production of targeted DNA scissors
Brionna McGorman, Dublin City University

Question 21

12.30-13.00 Discussion

Accepted Answer

Chairs: Victor E. Marquez, PhD, Chemical Biology Lab, NCI, NIH & Piet Herdewijn, PhD, KU Leuven

Question 22

Is this the Stockholm IRT in a virtual format?

Accepted Answer

No, this is an additional meeting with a brand new agenda.  The meeting in Stockholm has been rescheduled and will take place August 28-31, 2022. Click here (https://www.irt2021.se/)for more details.

Question 23

13.00-13.15 Break / Networking

Question 24

13.55-14.10 Break / Networking

Question 25

13.15-14.25  Session III

Accepted Answer

Co-chairs: 
Suzanne Peyrottes, PhD, 
Université de Montpellier 
and Katherine Seley-Radtke, PhD, 
University of Maryland, Baltimore County
 
13.15-13.25
Enantioselective organocatalytic synthesis of non natural nucleosides by cross aldol addition
Leticia Lafuente, PhD, Universidad Nacional de Quilmes
13.25-13.35
Triazolo nucleotide analogues as new chemotype for CD73 inhibition
Rayane Ghoteimi, PhD, Université de Montpellier
13.35-13.45
Impact of Multivalency and Encapsulation of Affinity Reagents and Catalysts
Brea Manuel, Emory University
13.45-13.55
Biophysical and biological evaluations of G-quadruplex thrombin binding aptamers stabilized by charge-transfer interactions 
Kévan Pérez de Carvasal, Université de Montpellier
13.55-14.05
2′-Fluoroarabinocytosine substitutions promote the exclusive formation of a novel TC5 dimeric structure with i-motif characteristics
Roberto El-Khoury, McGill University
14.05-14.15
Investigating the impact of epitranscriptomic modifications on RNA ensembles        
Hala Abou Assi, PhD, Duke University
14.15-14.25
Efficient Post-Synthetic Preparation of Oligonucleotide Conjugates via One-pot Diselenide-Selenoester Ligation-Deselenization/Alkylation
Christopher Liczner, MSc., Concordia University

Question 26

14.10-15.30 Session VII

Accepted Answer

Chair: Yitzhak Tor, PhD, University of California, San Diego
 
14.10-14.30
A Natural Riboswitch Scaffold with Methyltransferase Activity
Ronald Micura, PhD, University of Innsbruck  
14.30-14.50
RNA Functionalization via an Expanded Genetic Alphabet
Stephanie Kath-Schorr, PhD, University of Cologne

Ribozyme Gene Switches for Biosensing and Regeneration Studies
Maureen McKeague, PhD, McGill University   
 
15.10-15.30
Rapid Synthesis and Delivery of Antisense Oligonucleotides Enabled by Machine Learning
Bradley L. Pentelute, PhD, Massachusetts Institute of Technology

Question 27

If I submitted an abstract for the IRT in Stockholm, will my abstract be transferred for this meeting?"

Accepted Answer

No, you must submit a new abstract for the virtual symposium.

Question 28

15.30-16.00 Discussion

Accepted Answer

Chair: Yitzhak Tor, PhD, University of California, San Diego

Question 29

14.25-15.25 Session IV

Accepted Answer

Chair: Jean-Jacques Vasseur, PhD, Université de Montpellier
 
14.25-14.45
Enzymatic Photocaging of Nucleic Acids: A Strategy for Controlling Methyltransferase Target Sites by Light
Andrea Rentmeister, PhD, University of Münster
14.45-15.05
Stealth Fluorescence Labeling for Live-Cell Imaging in RNA-based Therapeutics
Marcus Wihelmsson, PhD, Chalmers University Technology
15.05-15.25
Light as a Tool for Understanding Biological Processes
Olalla Vázquez, PhD, Philipps-Universität Marburg

Question 30

Do you have any sponsorship opportunities?

Accepted Answer

Yes! Please email us at info@is3na.org (mailto:info@is3na.org)and we will be happy to contact you with the sponsorship prospectus.

Question 31

What’s the plan for the 2022 IRT?

Accepted Answer

The Stockholm IRT has been rescheduled to August 28-31, 2022. Mark your calendars and visit this website (https://www.irt2021.se/)for more information.

Question 32

16.00-16.20 Closing Remarks

Accepted Answer

Triumph of Nucleic Acids
David Corey, PhD, UT Southwestern

Question 33

15.25-15.45 Closing Remarks

Accepted Answer

Nucleosides, Nucleotides and Human Health
Víctor E. Marquez, PhD, Chemical Biology Lab, NCI, NIH

Question 34

16.20-16.30 Symposium Closing

Accepted Answer

Mano Manoharan, PhD, IS3NA President
Alnylam Pharmaceuticals
Masad J. Damha, PhD, IS3NA Immediate Past President
McGill University

Question 35

15.45-16.45 Virtual Networking & Social Meetups

Question 36

16.30-17.30 Virtual Networking & Social Meetups

​

Agenda